Skip to main content

Two targets or one? CAR-T in Lupus Nephritis

Dr. Henrique Dalmolin | Abstract 1215 |ACR 2026

Transcription

Hello, I'm Ehikami. I'm a rheumatologist from São Paulo and I'm in the coverage of ACR 2026 by RheumNow. Today I'm going to talk about dual target therapy, especially using CAR-T therapy for lupus nephritis.

First, the idea: most CAR-T in lupus targets only CD19, which removes B cells, but some plasma cells do not have CD19. They can survive and keep making antibodies, but a second target like BCMA can remove these cells too. So the goal is to get a deeper reset.

Abstract 105 from China tested a CAR-T against CD19 and BCMA. So we are talking about dual target CAR-T. It is off-the-shelf. It's made from a healthy donor. 16 patients with lupus nephritis — especially talking about the results right now — 11 of them had achieved complete renal response, 69% of the patients at 9 months. All patients were on 5 mg of prednisone or less. CRS was mild, and these patients did not have any neurotoxicity because of the treatment.

So what's my read? My read is that dual targeting of CD19 and BCMA makes sense. Two targets make sense because some autoantibodies are produced by plasma cells, so only targeting CD19 cannot bring the right result for these patients. Another point that is important is that this is an off-the-shelf therapy, so a lot of patients can receive this without needing to stay at the hospital or time for manufacturing.

So I'm Ehikami. I'm very glad to be with you here at RheumNow. Thank you.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×